Efficacy of intravenous ciprofloxacin in patients with febrile neutropenia refractory to initial therapy

References

• Masaoka T. Conclusions and recommendations: Evidence-based recommendations on antimicrobial use in febrile neutropenia in Japan. Int J Hematol 1998; 68: S29–S31
   PubMed Web of Science ®Google Scholar
• Tamura K, Matsuoka H, Tsukada J, Masuda M, Ikeda S, Matsuishi E, Kawano F, Izumi Y, Uike N, Utsunomiya A, Saburi Y, Shibuya T, Imamura Y, Hanada S, Okamura S, Gondoh H, Kyushu Hematology Organization for Treatment (K-HOT) Study Group. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of fourth-generation cephalosporin + aminoglycosides: Comparative study. Am J Hematol 2002; 71: 248–255
   PubMed Web of Science ®Google Scholar
• Elkhaili H, Kamili N, Linger L, Leveque D, Pompei D, Monteil H, Jehl F. In vitro time-kill curves of cefepime and cefpirome combined with amikacin, gentamicin or ciprofloxacin against Klebsiella pneumoniae producing extended-spectrum beta-lactamase. Chemotherapy 1997; 43: 245–253
   PubMed Web of Science ®Google Scholar
• Hirakata Y, Izumikawa K, Yamaguchi T, Takemura H, Tanaka H, Yoshida R, Matsuda J, Nakano M, Tomono K, Maesaki S, Kaku M, Yamada Y, Kamihira S, Kohno S. Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo-β-lactamase gene blaIMP. Antimicrob Agents Chemother 1998; 42: 2006–2011
   PubMed Web of Science ®Google Scholar
• Physicians' Desk Reference® entry for CIPRO® I.V. (Bayer) (ciprofloxacin), For Intravenous Infusion. Bayer Health Care Bayer Pharmaceuticals Corporation, 400 Morgan Lane, West Haven, CT 06516, USA
   Google Scholar
• Hughes W T, Armstrong D, Bodey G P, Brown A E, Edwards J E, Feld R, Pizzo P, Rolston K V, Shenep J L, Young L S. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25: 551–573
   PubMed Web of Science ®Google Scholar
• Fleming T R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143–151
   PubMed Web of Science ®Google Scholar
• Hughes W T, Armstrong D, Bodey G P, Bow E J, Brown A E, Calandra T, Feld R, Pizzo P A, Rolston K V, Shenep J L, Young L S. 2002 guideline for the use of antimicrobial agent in neutropenic patients with cancer. Clin Infect Dis 2002; 35: 730–751
   Web of Science ®Google Scholar
• Tamura K, Imajo K, Akiyama N, Suzuki K, Urabe A, Ohyashiki K, Tanimoto M, Masaoka T, Japan Febrile Neutropenia Study Group. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis 2004; 39: S15–S24
   PubMed Web of Science ®Google Scholar
• Hughes W T, Armstrong D, Bodey G P, Feld R, Mandell G L, Meyers J D, Pizzo P A, Schimpff S C, Shenep J L, Wade J C, Young L S, Yow M D. From the Infectious Diseases Society of America. Guideline for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161: 381–396
   PubMed Web of Science ®Google Scholar
• Griggs J J, Blair E A, Norton J R, Rowe J M, Flesher W R, Betts R F. Ciprofloxacin plus piperacillin is an equally effective regimen for empiric therapy in febrile neutropenic patients compared with standard therapy. Am J Hematol 1998; 58: 293–297
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Bassaris H P, Petrikkos G, Busch W, Voulgarelis M, Antoniadou A, Grouzi E, Zoumbos N. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy. Antimicrob Agents Chemother 2000; 44: 3264–3271
   PubMed Web of Science ®Google Scholar
• Peacock J E, Herrington D A, Wade J C, Lazarus H M, Reed M D, Sinclair J W, Haverstock D C, Kowalsky S F, Hurd D D, Cushing D A, Harman C P, Donowitz G R. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. Ann Intern Med 2002; 137: 77–86
   PubMed Web of Science ®Google Scholar
• Kern W V, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341: 312–318
   PubMed Web of Science ®Google Scholar
• Kohno S, Yanagihara K, Tomono K, Ameshima S, Demura Y, Ishizaki T, Yamaguchi K, Watanabe H, Tsukada H, Suzuki E, Gejo F. Clinical efficacy of ciprofloxacin in patients with respiratory tract infection refractory to penicillin or cephem: carbapenem-controlled clinical study. Jpn J Chemother 2004; 52: 309–317
   Google Scholar
• Tamura K. Initial empirical antimicrobial therapy: duration and subsequent modifications. Clin Infect Dis 2004; 39: S59–S64
   PubMed Web of Science ®Google Scholar